This is a demo store. No orders will be fulfilled.
Companion Diagnostics (CDx) is Revolutionizing the Global Clinical Next-generation Sequencing (NGS) Market
Companion Diagnostics (CDx) is Revolutionizing the Global Clinical Next-generation Sequencing (NGS) Market
Next-generation Blockchain-Powered Genomic Data Marketplaces are Creating New Growth Opportunities
03-Feb-2021
North America
Description
2020 will be remembered for the COVID-19 pandemic, masks, social distancing protocol, alternate care sites, Moderna, Pfizer, BioNTech, AstraZeneca, RT-PCR, and serology testing (or all the above). However, in the midst of our response to the global pandemic, remarkable advancements were made in another great frontier in medicine that remains unconquered—cancer. These advancements mark the dawn of precision diagnostics to deliver the promise of personalized medicine. The key enablers were the game-changing advancements in next-generation (NGS) workflow solutions, defining a new era in mutation testing, early detection, liquid biopsy, pan-cancer in vitro diagnostic (IVD) assays, companion diagnostics (CDx) tests, and blockchain-based direct-to-consumer (DTC) services. The role of liquid biopsy NGS tests will gain significance in the coming age of minimal residue disease monitoring.
2020 saw a rising trend of consolidation; 3 high-value acquisitions took place—Illumina and Grail (announced); Invitae and ArcherDx; and Exact Sciences and Thrive Earlier Detection. With the arrival of early blood-based cancer screening assays and advancements in NGS bioinformatics, the market holds immense potential. Additional consolidations are expected in future, particularly in early detection and artificial intelligence (AI)-enabled diagnostics at the point of care (PoC).
North America (the United States) is the largest market. Strong infrastructure, favorable coverage policies, and early approvals for NGS-based CDx act as market growth drivers. Asia-Pacific is in the early stage of growth; however, an increase in public-private partnerships, biopharma developers’ increasing focus on CDx tests, and the need to develop in-house multi-gene panels are setting the tone for widespread guideline-recommended genomic testing.
Market leader Illumina (with its planned acquisition of Grail) will reignite its growth engine by changing its value proposition from ‘research tools company’ to ‘clinical diagnostics supplier’. As the workflow solutions segment continues to grow at an explosive rate, the genomic data marketplace will become a key growth opportunity that market participants can explore.
Macroeconomic models aim to improve and increase the amount of data available for basic genomic science and personalized genomic medicine and monetize data sharing initiatives by providing patients greater access control to data through a cooperative marketplace. This will improve clinical uptake, catalyze innovation, and build trust in the ecosystem.
Immediate growth opportunity lies in the development of NGS-based CDx tests. Hence, assay developers are encouraged to adopt a multi-disciplinary, design-focused approach to test menus, assay design, and overall workflow. A holistic approach is encouraged, and this must cover patient need, physician perspective, and the integration of test results with an electronic medical record system. Simultaneously, more efforts to create awareness through partnerships, education, and outreach initiatives will ensure consistent clinical uptake.
Exploring the possibilities of delivering CDx tests at the PoC by leveraging existing standard products and tailoring them to be specific to an analyte of interest, supported by smartphone apps and readers, could be a winning strategy. As clinical and economic utility continues to improve, new care delivery models will emerge (for example, conversational AI-enabled diagnostics at the PoC) and simplify real-world clinical genomic data, thereby helping to develop a better understanding of disease areas and treatment decisions.
Author: Amartya Bose
RESEARCH: INFOGRAPHIC
This infographic presents a brief overview of the research, and highlights the key topics discussed in it.Click image to view it in full size
Table of Contents
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the Clinical NGS Market
Growth Opportunities Fuel the Growth Pipeline Engine™
Scope of Analysis
Market Segmentation
Key Competitors—Global
Key Growth Metrics for Clinical NGS
Growth Drivers for Clinical NGS
Growth Restraints for Clinical NGS
Forecast Assumptions—General Factors under Consideration
Forecast Assumptions—Clinical NGS
Forecast Assumptions—Clinical NGS (continued)
Aspirational Revenue Forecast—Clinical NGS
Conservative Revenue Forecast—Clinical NGS
Aspirational Revenue Forecast by Industry Vertical—Clinical NGS
Conservative Revenue Forecast by Industry Vertical—Clinical NGS
Aspirational Revenue Forecast by Region—Clinical NGS
Conservative Revenue Forecast by Region—Clinical NGS
Revenue Forecast Analysis by Region—Clinical NGS
Revenue Forecast Analysis by Region—Clinical NGS (continued)
Competitive Environment—Clinical NGS
Revenue Share—Clinical NGS
Revenue Share Analysis—Clinical NGS
Competitive Environment—Clinical NGS
Key Growth Metrics for the Clinical NGS Workflow Solutions Segment
Aspirational Revenue Forecast—Clinical NGS Workflow Solutions
Conservative Revenue Forecast—Clinical NGS Workflow Solutions
Forecast Analysis—Clinical NGS Workflow Solutions
Key Growth Metrics for the Clinical NGS Instruments Segment
Aspirational Revenue Forecast—Clinical NGS Instruments
Conservative Revenue Forecast—Clinical NGS Instruments
Forecast Analysis—Clinical NGS Instruments
Revenue Share by Disease Area—Clinical NGS
Key Disease Area Discussions
Growth Opportunity 1: Multi-Gene Panels and NGS Tests for NSCLC, Prostate Cancer, and Colorectal Cancer Treatment Pathways
Growth Opportunity 1: Multi-Gene Panels and NGS Tests for NSCLC, Prostate Cancer, and Colorectal Cancer Treatment Pathways (continued)
Growth Opportunity 2: NGS-based CDx for Targeted Cancer Therapeutics in Asia-Pacific
Growth Opportunity 2: NGS-based CDx for Targeted Cancer Therapeutics in Asia-Pacific (continued)
Growth Opportunity 3: DTC WGS Testing and Services
Growth Opportunity 3: DTC WGS Testing and Services (continued)
Growth Opportunity 4: Next-Generation Blockchain-based Genomic Data Marketplaces
Growth Opportunity 4: Next-Generation Blockchain-based Genomic Data Marketplaces (continued)
Conclusions—Key Takeaways
Your Next Steps
Why Frost, Why Now?
List of Exhibits
List of Exhibits (continued)
Legal Disclaimer
Popular Topics
Deliverable Types | Mega Trends |
---|---|
No Index | No |
Podcast | No |
Author | Amartya Bose |
Industries | Healthcare |
WIP Number | K555-01-00-00-00 |
Is Prebook | No |
GPS Codes | 9600-B1,9562-B1,9573-B1,9627-B1 |